ALK expects to have approved peanut allergy vaccine in 2030

Head of R&D at ALK Henrik Jacobi thinks the decision to move into peanut allergies makes sense, as the firm already has a lot of experience of developing tablet-based vaccines.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK to start phase I trial of peanut allergy tablet vaccine
For subscribers
ALK finds replacement for long-time North America lead
For subscribers